16.02.2017 • News

Imperial acquires Kenyan pharmaceutical distributor Surgipharm

Imperial Logistics, a wholly owned division of Imperial Holdings, has entered into an agreement to acquire a 70% interest in Surgipharm, a leading pharmaceutical distributor in Kenya, for a cash consideration of 35 million USD.

Surgipharm, which is headquartered in Nairobi, is a distributor of pharmaceutical, medical, surgical and allied supplies in Kenya, with an annual turnover of approximately 70 million USD. The company was established in 1985 and has grown to become one of the leading pharmaceutical distribution companies in Kenya, with offices strategically located in Nairobi and Mombasa.

With a workforce of over 330 employees, warehousing space in excess of 4,700 square meters and an own transport fleet, the business caters for the needs of all pharmaceutical distribution channels in the country.Dr. Vijai Maini will continue as the Managing Director, and Mr. Vipin Shah and Rakesh Vinayak will continue as Directors in their current roles post the transaction.

This transaction is in line with Imperial’s African growth strategy to be a significant route-to-market partner of multi-national companies in the consumer goods and pharmaceutical sectors in Southern, East and West Africa. Surgipharm also complements Imperial’s prior acquisitions in the pharmaceutical sector being Imperial Health Sciences, Eco Health (Nigerian pharmaceutical distributor) and Imres (Netherlands-based pharmaceutical wholesaler).

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read